RECKITT BENCKIS/S (OTCMKTS:RBGLY) has been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company.
A number of brokerages have issued reports on RBGLY. Zacks Investment Research upgraded RECKITT BENCKIS/S from a “sell” rating to a “hold” rating in a research note on Friday, August 17th. BNP Paribas upgraded RECKITT BENCKIS/S from a “neutral” rating to an “outperform” rating in a research note on Tuesday, November 20th.
Shares of OTCMKTS:RBGLY traded down $0.10 during midday trading on Tuesday, hitting $17.05. The company had a trading volume of 152,463 shares, compared to its average volume of 239,613. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.50 and a current ratio of 0.68. RECKITT BENCKIS/S has a 12-month low of $15.14 and a 12-month high of $21.79.
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.